This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?
This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?
This week, we will discuss the NOSTONE trial. Another renal reversal that will be practice changing. Should we stop using HCTZ for kidney stone prevention.
This week, we will discuss the STOP ACEi trial, a poster from Kidney Week but published in the NEJM. Should we stop RAS inhibition at an arbitrary GFR or bravely carry on?
This week, we will discuss The ADVOR trial, possibly the only randomized, placebo controlled trial of sequential nephron blockade ever. Could the use of acetazolamide in acute decompensated heart failure make a difference?
This week, we will discuss the CLICK trial. Another medical reversal - showing that this old and cheap drug, chlorthalidone, might actually work in advanced CKD. Click through to read more.
This week, we discuss the discovery that peritoneal membrane water transport, and PD outcomes, are influenced by genetic variations in the Aquaporin 1 channel.
This week, we will discuss the SSASS trial. in which a simple switch of table salt with a K-enriched salt works miracles. Is it about the sodium or the potassium?
This week, we will discuss the hot off the press. On the quest to solve the disparity created by GFR calculations, we discuss the new equations. Is it time to drop the race coefficient, or is it time to drop serum creatinine entirely?
This week, we will discuss the ADVOCATE trial. Avacopan is not just a flash in the pan? We hope so, having won the RheumMadness and offering a steroid free hope.
This week, we will discuss the CONFIRM trial. It was supposed to confirm the role of terlipressin in reversing hepatorenal syndrome…unfortunately it hit the nephrology nihilism wall.
This is the first, yes, the first time we are discussing a trial in SLE patients. Belimumab, which inhibits BAFF also called BLyS (hence the BLISS trials) in lupus nephritis. Added to a background of standard therapy - what does it give us? Let’s dive in.
This week, we will discuss whether the time has come to add mineralocorticoid antagonism to the RAS armamentarium. Can we surmount the hyperkalemia which is the commonest problem with these drugs? Let’s find out with FIDELIO.
SGLT2 inhibitors lower MACE in Diabetes. Then they decrease kidney failure in DM. Then Heart Failure in DM and non-DM. And now decrease kidney failure in nonDM too! Let’s see how strong the data really is